Pfizer and AstraZeneca, new study on efficacy against Indian variant

Pfizer and AstraZeneca vaccines proved highly effective against the Indian variant of Covid after two doses of the product. This was revealed by a study by the British health authorities, reports the BBC, specifying that with the second dose the two vaccines ensured a level of protection against the symptoms of the disease of the Indian variant equal to that recorded for the English variant. However, the two vaccines proved to be only 33% effective against the Indian strain three weeks after the first injection, compared to 50% effective against the English one. The Pfizer vaccine was found to be 88% effective in stopping the symptomatic disease of the Indian variant two weeks after the second dose, compared to 93% guaranteed compared to the variant that emerged in Kent. Astrazeneca revealed an efficacy of 60% against the Indian variant, 66% against the British one, therefore lower percentages but which may derive from the fact – according to the authors of the study – that the inoculations of the second dose of Astrazeneca started later than to those of Pfizer, which had received approval earlier.